- Phase 3 result
- 83% reduction in monthly HAE attacks vs placebo
Pharvaris develops oral treatments for hereditary angioedema, a rare condition currently managed with injections. The company is based in Leiden and listed on Nasdaq. Its CHAPTER-3 pivotal trial, reported in September 2026, cut monthly attack rates by 83% against placebo, and it plans to file for marketing authorisation from the first half of 2027 without licensing the programme to a larger partner.